{"filing":{"accession_number":"0001628280-26-043042","cik":"0001842952","ticker":"CNTX","company_name":"Context Therapeutics Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"cntx-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/cntx-20260615.htm"},"events":[{"id":10958,"run_id":9603,"accession_number":"0001628280-26-043042","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Context Therapeutics announced positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate, disclosed under Item 8.01 (Other Events).","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7417,"accession_number":"0001628280-26-043042","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate. While clinical trial results are material to biotech investors and would affect the total mix of information available, this does not fit cleanly into the standard taxonomy categories (earnings_release applies to financial results, not clinical data). The event is disclosed under Item 8.01 (Other Events) rather than a dedicated Item, supporting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:20:08.622564+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7416,"accession_number":"0001628280-26-043042","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a Regulation FD disclosure of an updated corporate presentation posted to the company's website. The filing contains only a routine administrative disclosure with standard safe-harbor language disclaiming incorporation by reference and Section 18 liability. Without visibility into the presentation content itself, this appears to be a standard investor relations update rather than a material event triggering a specific 8-K category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:20:08.622564+00:00","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-15"},{"id":7417,"accession_number":"0001628280-26-043042","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate. While clinical trial results are material to biotech investors and would affect the total mix of information available, this does not fit cleanly into the standard taxonomy categories (earnings_release applies to financial results, not clinical data). The event is disclosed under Item 8.01 (Other Events) rather than a dedicated Item, supporting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:20:08.622564+00:00","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-15"}]}